Compare DexCom, Inc. (DXCM) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while iShares 1 3 Year Treasury Bond ETF trades at $81.2 (market cap $26.68B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| DXCM | SHY | |
|---|---|---|
Market Cap | $31.86B | $26.68B |
Volume | 3,607,070 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $83.18 |
52-Week Low | $54.84 | $81.05 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
SHY, a US stock, trades at $81.20 with minimal daily movement (+0.05%). The technical outlook is bearish, with moving averages signaling downward pressure and key indicators like the ADX_12 at 50.39 suggesting a strong trend. Recent corporate actions include scheduled dividends through late 2026, though financial ratios (P/E, P/S, etc.) are unavailable in the current snapshot. Market sentiment is influenced by broader bond market volatility, with news highlighting rising Treasury yields and geopolitical tensions impacting inflation expectations.
The outlook for SHY is cautious amid a bearish technical setup and macroeconomic headwinds, including higher interest rates and inflation concerns. Opportunities may arise from its dividend payments, but risks include sustained bond market sell-offs and economic uncertainty. Investors should weigh the stock's stability against potential volatility from external factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
